Recurrent Intrahepatic Cholangiocarcinoma – Review
Intrahepatic cholangiocarcinoma (ICC) is the second-most common primary liver malignancy after hepatocellular carcinoma. While surgical resection with negative margin is the only curative treatment, ICC has very high rate of recurrence, up to 60-70% after curative resection. We reviewed the current...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.776863/full |
| _version_ | 1830187420217245696 |
|---|---|
| author | Yuki Bekki Dagny Von Ahrens Hideo Takahashi Myron Schwartz Ganesh Gunasekaran Ganesh Gunasekaran |
| author_facet | Yuki Bekki Dagny Von Ahrens Hideo Takahashi Myron Schwartz Ganesh Gunasekaran Ganesh Gunasekaran |
| author_sort | Yuki Bekki |
| collection | DOAJ |
| description | Intrahepatic cholangiocarcinoma (ICC) is the second-most common primary liver malignancy after hepatocellular carcinoma. While surgical resection with negative margin is the only curative treatment, ICC has very high rate of recurrence, up to 60-70% after curative resection. We reviewed the current data available on risk factors for ICC recurrence, recurrence pattern (location and timing), treatment options, and future directions. The risk factors for recurrence include elevated preoperative CA19-9, presence of liver cirrhosis, nodal metastasis, positive margins, and vascular invasion. Understanding different recurrence patterns, timing course, and risk factors for early recurrence is important to tailor postoperative surveillance and select treatment strategies including systemic or locoregional therapy. Re-resection can be considered for a selected patient population at experienced centers, and can yield long-term survival. ICC remains a dismal disease given the high likelihood of recurrence. Advances in our understanding of the genomic landscape of ICC are beginning to identify targetable alterations in ICC in subsets of patients that allow for personalized treatment. |
| first_indexed | 2024-12-17T22:28:11Z |
| format | Article |
| id | doaj.art-18d9a60fdf6a40a49fe7d39f0f0349c3 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-17T22:28:11Z |
| publishDate | 2021-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-18d9a60fdf6a40a49fe7d39f0f0349c32022-12-21T21:30:17ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-10-011110.3389/fonc.2021.776863776863Recurrent Intrahepatic Cholangiocarcinoma – ReviewYuki Bekki0Dagny Von Ahrens1Hideo Takahashi2Myron Schwartz3Ganesh Gunasekaran4Ganesh Gunasekaran5Division of Liver Surgery, Recanati/Miller Transplantation Institute, The Icahn School of Medicine at Mount Sinai, New York, NY, United StatesDivision of Liver Surgery, Recanati/Miller Transplantation Institute, The Icahn School of Medicine at Mount Sinai, New York, NY, United StatesDepartment of Surgery, Mount Sinai South Nassau, Oceanside, NY, United StatesDivision of Liver Surgery, Recanati/Miller Transplantation Institute, The Icahn School of Medicine at Mount Sinai, New York, NY, United StatesDivision of Liver Surgery, Recanati/Miller Transplantation Institute, The Icahn School of Medicine at Mount Sinai, New York, NY, United StatesDepartment of Surgery, Mount Sinai South Nassau, Oceanside, NY, United StatesIntrahepatic cholangiocarcinoma (ICC) is the second-most common primary liver malignancy after hepatocellular carcinoma. While surgical resection with negative margin is the only curative treatment, ICC has very high rate of recurrence, up to 60-70% after curative resection. We reviewed the current data available on risk factors for ICC recurrence, recurrence pattern (location and timing), treatment options, and future directions. The risk factors for recurrence include elevated preoperative CA19-9, presence of liver cirrhosis, nodal metastasis, positive margins, and vascular invasion. Understanding different recurrence patterns, timing course, and risk factors for early recurrence is important to tailor postoperative surveillance and select treatment strategies including systemic or locoregional therapy. Re-resection can be considered for a selected patient population at experienced centers, and can yield long-term survival. ICC remains a dismal disease given the high likelihood of recurrence. Advances in our understanding of the genomic landscape of ICC are beginning to identify targetable alterations in ICC in subsets of patients that allow for personalized treatment.https://www.frontiersin.org/articles/10.3389/fonc.2021.776863/fullintrahepatic cholangiocarcinomarecurrencemanagementrisk factors for recurrencere-resection of the liver |
| spellingShingle | Yuki Bekki Dagny Von Ahrens Hideo Takahashi Myron Schwartz Ganesh Gunasekaran Ganesh Gunasekaran Recurrent Intrahepatic Cholangiocarcinoma – Review Frontiers in Oncology intrahepatic cholangiocarcinoma recurrence management risk factors for recurrence re-resection of the liver |
| title | Recurrent Intrahepatic Cholangiocarcinoma – Review |
| title_full | Recurrent Intrahepatic Cholangiocarcinoma – Review |
| title_fullStr | Recurrent Intrahepatic Cholangiocarcinoma – Review |
| title_full_unstemmed | Recurrent Intrahepatic Cholangiocarcinoma – Review |
| title_short | Recurrent Intrahepatic Cholangiocarcinoma – Review |
| title_sort | recurrent intrahepatic cholangiocarcinoma review |
| topic | intrahepatic cholangiocarcinoma recurrence management risk factors for recurrence re-resection of the liver |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.776863/full |
| work_keys_str_mv | AT yukibekki recurrentintrahepaticcholangiocarcinomareview AT dagnyvonahrens recurrentintrahepaticcholangiocarcinomareview AT hideotakahashi recurrentintrahepaticcholangiocarcinomareview AT myronschwartz recurrentintrahepaticcholangiocarcinomareview AT ganeshgunasekaran recurrentintrahepaticcholangiocarcinomareview AT ganeshgunasekaran recurrentintrahepaticcholangiocarcinomareview |